Drug facts

Semaglutide, heartburn, acid reflux and burping

By David Chen·Editor·Reviewed September 2026

The label’s words for it²

The prescribing information uses clinical terms: eructation, the medical word for belching; dyspepsia, for indigestion; and gastroesophageal reflux disease, for stomach contents coming back up into the esophagus. The Medication Guide, written for the person taking the drug, uses plainer ones. Its list of the most common side effects includes “belching,” “heartburn” and “upset stomach.”

How common it was on Wegovy¹

Four rows in the label’s table of reactions reported in 2% or more of adults bear on this question. The arm was 2,116 adults on semaglutide 2.4 mg against 1,261 on placebo.

Burping is the row to notice. Its placebo rate is printed as less than 1%, so almost none of the 7% is background: it is one of the few rows in the table where the drug accounts for nearly all of the figure. Reflux disease is the opposite case: 3% reported it on placebo, against 5% on the drug. The gastritis row, by the label’s footnote, groups chronic, erosive and reflux gastritis together.

In the trial of adolescents aged 12 and older, reflux disease was reported by 4% against 2% on placebo, and eructation by 4% against none.

On Ozempic³

The Ozempic label lists these reactions below its 5% table, from its placebo-controlled trials in adults with type 2 diabetes. It gives each as placebo, then 0.5 mg, then 1 mg:

The rates are lower than on Wegovy, and at 1 mg they are lower than at 0.5 mg for all three. These are different doses in a different population, in trials of a different length, so the two labels’ figures are not a dose-response curve and neither label presents them as one. How the two approvals differ →

About “sulfur burps”⁴

The phrase is not the label’s. A search of the full Wegovy document, prescribing information and Medication Guide together, finds “sulfur,” “burp,” “smell” and “odor” zero times each. The Ozempic document is the same. The label records that belching happened and how often. It says nothing about how a belch smells, and gives no cause for it.

The one digestive mechanism the label does state is that semaglutide delays gastric emptying, which it raises in its warnings about anesthesia and sedation and about oral medicines. It does not connect that to belching or reflux, and this page does not make the connection on its behalf.

When it was reported¹

The label groups these with the other digestive reactions reported more often on semaglutide than placebo (dyspepsia, abdominal pain, abdominal distension, eructation, flatulence, reflux disease, gastritis, hemorrhoids and hiccups) and says they were most often reported during dose escalation. That is a statement about timing during the climb through the four-week steps. It is not a promise that they stop, and the label gives no duration.

When it is not just heartburn²

The Medication Guide names several serious side effects that involve pain in the stomach area. It describes pancreatitis as severe pain in the abdomen that will not go away, sometimes felt through to the back. It lists pain in the upper abdomen among the symptoms of gallbladder problems. It also warns of stomach problems that are severe or will not go away. Those are set out on the pancreatitis page, with the label’s own wording.

What none of this covers

Nothing here is medical advice, and this page suggests no remedy, food change or antacid. Whether a symptom needs managing is a question for the prescriber. The full table is on side effects. See the medical disclaimer.